Dateline City:
BOSTON
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced new data from HIV/HCV co-infected patients in the
ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy
and safety of Merck's all-oral, once-daily regimen combining MK-5172, an
investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and
MK-8742, an investigational HCV NS5A replication complex inhibitor.
Language:
English
Contact:
MerckMedia:Caroline Lappetito, 267-305-7639orIan McConnell, 908-423-3046orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more